Text Size
60 studies found for:    Open Studies | "Amyloidosis"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Recruiting Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed
Condition: Primary Systemic Amyloidosis
Interventions: Drug: Lenalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
22 Recruiting Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Condition: Relapsed or Refractory Systemic Light Chain Amyloidosis
Interventions: Drug: MLN9708;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Cyclophosphamide;   Drug: Thalidomide;   Drug: Lenalidomide
23 Not yet recruiting Tolerability and Efficacy of a Combination of Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy
Conditions: Amyloidosis; Heart (Manifestation);   Senile Cardiac Amyloidosis
Intervention: Drug: Tauroursodeoxycholic Acid and Doxycycline
24 Recruiting High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease
Condition: Primary Amyloidosis of Light Chain Type
Interventions: Device: High Cut-off Hemodialysis;   Drug: Chemotherapy
25 Recruiting Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
Condition: Primary Amyloidosis of Light Chain Type
Intervention: Drug: Pomalidomide and Dexamethasone
26 Recruiting Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis
Condition: Primary Amyloidosis of Light Chain Type
Interventions: Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias);   Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG
27 Recruiting Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Conditions: Light Chain Deposition Disease (LCDD or MIDD);   Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD);   Monoclonal Immunoglobulin Deposition Disease (MIDD);   Amyloidosis
Intervention: Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
28 Recruiting Screening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy
Conditions: Polyneuropathies;   Amyloidosis;   Amyloid Neuropathies;   Amyloidosis, Familial;   Metabolic Diseases
Intervention:
29 Recruiting A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: Pomalidomide;   Drug: Dexamthasone
30 Recruiting Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Conditions: Plasma Cell Dyscrasias;   Monoclonal Gammopathy of Undetermined Significance;   AL Amyloidosis;   Multiple Myeloma
Intervention: Procedure: tissue banking
31 Recruiting Trial to Evaluate Safety and Tolerability of ALN-TTR02 in Transthyretin (TTR) Amyloidosis
Condition: TTR-mediated Amyloidosis
Intervention: Drug: ALN-TTR02
32 Recruiting Study of Oral MLN9708 in Adult Patients With Relapsed or Refractory Light Chain Amyloidosis
Condition: Light-Chain Amyloidosis
Intervention: Drug: MLN9708
33 Recruiting Pomalidomide, Bortezomib, and Dexamethasone as First-Line Treatment in Treating Patients With Amyloid Light-Chain Amyloidosis or Light Chain Deposition Disease
Conditions: Light Chain Deposition Disease;   Primary Systemic Amyloidosis
Interventions: Drug: pomalidomide;   Drug: bortezomib;   Drug: dexamethasone
34 Recruiting Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)
Condition: Amyloidosis
Intervention: Drug: Bortezomib
35 Recruiting Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
Conditions: Multiple Myeloma;   Primary Amyloidosis
Interventions: Drug: Melphalan;   Procedure: Stem Cell Infusion;   Behavioral: Questionnaires;   Drug: Granulocyte-colony stimulating factor (G-CSF);   Procedure: Apheresis
36 Not yet recruiting Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
Condition: Myeloma
Interventions: Drug: Pomalidomide;   Drug: Melphalan;   Drug: Dexamethasone;   Behavioral: Questionnaires
37 Unknown † Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: therapeutic immune globulin;   Other: laboratory biomarker analysis
38 Not yet recruiting Progression of Renal Amyloidosis of FMF and Relation to Serum SAA Level
Condition: Observational
Intervention:
39 Recruiting Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Conditions: Chronic Kidney Disease;   Acute Myeloid Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Chronic Myelogenous Leukemia (CML);   Chronic Lymphocytic Leukemia (CLL);   Non-Hodgkin's Lymphoma (NHL);   Hodgkin Disease;   Multiple Myeloma;   Myelodysplastic Syndrome (MDS);   Aplastic Anemia;   AL Amyloidosis;   Diamond Blackfan Anemia;   Myelofibrosis;   Myeloproliferative Disease;   Sickle Cell Anemia;   Autoimmune Diseases;   Thalassemia
Intervention: Procedure: Haploidentical Bone Marrow/Kidney
40 Recruiting Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
Conditions: Extramedullary Plasmacytoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Primary Systemic Amyloidosis;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: cisplatin;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: bortezomib;   Drug: thalidomide;   Drug: melphalan;   Procedure: autologous stem cell transplant
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years